NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Short Interest Down 30.0% in February

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) saw a large decrease in short interest in the month of February. As of February 13th, there was short interest totaling 392,037 shares, a decrease of 30.0% from the January 29th total of 559,856 shares. Based on an average daily volume of 152,582 shares, the short-interest ratio is currently 2.6 days. Based on an average daily volume of 152,582 shares, the short-interest ratio is currently 2.6 days.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Yorkville Advisors Global LP acquired a new stake in NeuroSense Therapeutics in the 4th quarter worth approximately $77,000. Squarepoint Ops LLC grew its stake in NeuroSense Therapeutics by 91.0% in the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock valued at $119,000 after buying an additional 45,450 shares during the last quarter. Jane Street Group LLC bought a new position in NeuroSense Therapeutics in the 2nd quarter worth $54,000. Finally, Two Sigma Investments LP bought a new position in NeuroSense Therapeutics in the 3rd quarter worth $26,000. Institutional investors and hedge funds own 1.04% of the company’s stock.

NeuroSense Therapeutics Stock Up 0.8%

Shares of NeuroSense Therapeutics stock traded up $0.01 during midday trading on Friday, reaching $0.91. 40,902 shares of the company’s stock traded hands, compared to its average volume of 172,336. NeuroSense Therapeutics has a 52 week low of $0.68 and a 52 week high of $2.60. The company’s 50 day simple moving average is $0.92 and its 200 day simple moving average is $1.05.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Wall Street Zen raised shares of NeuroSense Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, January 3rd. D. Boral Capital reissued a “buy” rating and set a $14.00 target price on shares of NeuroSense Therapeutics in a research note on Monday, December 22nd. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NeuroSense Therapeutics in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $14.00.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.